*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2020 | Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males Translational andrology and urology · preclinical | PMID 32257855 |
| 2015 | Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin Drug testing and analysis · preclinical | PMID 25869809 |
| 2015 | Detection of GHRP-2 and GHRP-6 in urine samples from athletes Drug testing and analysis · preclinical | PMID 25809000 |
| 2014 | Adult growth hormone deficiency: current concepts Neurologia medico-chirurgica · preclinical | PMID 25070016 |
| 2010 | Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by liquid chromatography/electrospray ionization tandem mass spectrometry Rapid communications in mass spectrometry : RCM · preclinical | PMID 20552695 |
| 2005 | Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men The Journal of clinical endocrinology and metabolism · preclinical | PMID 15699539 |
| 2004 | Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN Drugs in R&D · preclinical | PMID 15230633 |
| 2004 | Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide Arzneimittel-Forschung · preclinical | PMID 15646370 |
| 2002 | Gateways to clinical trials Methods and findings in experimental and clinical pharmacology · preclinical | PMID 12092009 |
| 1998 | Growth hormone-releasing peptide-2 (GHRP-2) does not act via the human growth hormone-releasing factor receptor in GC cells Endocrine · preclinical | PMID 9798733 |
| 1997 | Growth hormone-releasing peptides European journal of endocrinology · preclinical | PMID 9186261 |
| 1996 | GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans Journal of pediatric endocrinology & metabolism : JPEM · human | PMID 8887169 |
GHRP-2 (Growth Hormone-Releasing Peptide-2 (Pralmorelin)). Synthetic GH secretagogue (GHS-R agonist). Stimulates GH release; also raises appetite, cortisol, and prolactin to a moderate degree.
Commonly discussed uses: GH-axis research, diagnostic GH-secretagogue testing (Japan, as pralmorelin). There is both human and animal/preclinical research, though the depth and quality vary by indication. Note: most uses are not approved indications.
Mechanism: Synthetic GH secretagogue (GHS-R agonist). Stimulates GH release; also raises appetite, cortisol, and prolactin to a moderate degree.
Reported considerations: increased appetite, cortisol/prolactin rise, water retention, head-rush. There is both human and animal/preclinical research, though the depth and quality vary by indication. WADA-prohibited. Approved as a diagnostic agent (pralmorelin) in Japan; not approved in AU/US/UK for therapeutic use. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low 100mcg, typical 100-300mcg 1-3x/day, high 300mcg 3x/day. Administration: subcutaneous. Half-life: ~30-60 min.
Australian status: Not ARTG-registered; research; WADA prohibited. WADA-prohibited. Approved as a diagnostic agent (pralmorelin) in Japan; not approved in AU/US/UK for therapeutic use. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: 2ml BAC water per 5mg vial; storage: refrigerated.
Commonly discussed combinations (anecdotal for unapproved compounds): GHRP-2 + CJC-1295 (anecdotal GH-axis stack). Stacking increases interaction/safety uncertainty.